Water-soluble steroid compounds
Patent 4383992 Issued on May 17, 1983. Estimated Expiration Date: 
February 8, 2002. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
February 8, 2002. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References3079410 InventorApplicationNo. 06/346501 filed on 02/08/1982US Classes:514/174, -O-C-O- is part of a hetero ring (e.g., acetonide, etc.)514/176, Nitrogen containing hetero ring514/178, Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system514/179, Modified C-ring (except methyl in 13-position) (e.g., double bond containing, substituted, etc.)514/180, 9-position substituted514/181, 21-position substituted514/182, Oxygen single bonded to a ring carbon of the cyclopentanohydrophenanthrene ring system514/58, Dextrin or derivative514/778, Starch or derivative514/914, Inflammation536/103, Dextrin or derivative536/46, Dextrin derivatives540/52, The hetero ring consists of two nitrogens and three carbons and is ortho fused to the A ring540/53, Having -C(=X)-, wherein X is chalcogen, bonded directly at the 17-position of the cyclopentanohydrophenanthrene ring system540/63, The hetero ring is ortho-fused to the D ring540/69, Halogen bonded directly to the cyclopentanohydrophenanthrene ring system540/70, Oxygen bonded directly at the 11-position of the cyclopentanohydrophenanthrene ring system540/71Oxygen attached directly to the B ring or indirectly to the A or B ring by acyclic nonionic bondingExaminersPrimary: Roberts, Elbert L.Attorney, Agent or FirmInternational ClassesA61K 47/48 (20060101)A61K 31/57 (20060101) A61K 31/565 (20060101) C08B 37/00 (20060101) AbstractBeta-cyclodextrin forms a water-soluble complex or inclusion compound with steroid compounds having a molecular structure smaller than the interior cavity in the doughnut-shaped molecular structure of beta-cyclodextrin. The resulting inclusion compounds can be used for a variety of applications including aqueous topical ophthalmic preparations and topical dermatological ointments. |
| ||||||||||||||
